Working… Menu
Trial record 1 of 1 for:    ho141
Previous Study | Return to List | Next Study

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03226301
Recruitment Status : Active, not recruiting
First Posted : July 21, 2017
Last Update Posted : August 4, 2020
Nordic CLL Study Group
Information provided by (Responsible Party):
Stichting Hemato-Oncologie voor Volwassenen Nederland